Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

NICE Recommends Cytisine (Cytisinicline) Within The Treatments "More Likely" To Help Smokers Quit in Newly Updated Guidance


News provided by

Consilient Health

04 Feb, 2025, 06:14 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Feb. 4, 2025 /PRNewswire/ -- Proven smoking cessation treatment, Cytisine (also known as cytisinicline), has been classified among the "more likely" interventions to result in successful quitting for UK smokers in the latest version of The National Institute for Health and Care Excellence (NICE) tobacco guidelines (NG209).(1)

NICE's update mandates that local commissioners and providers of healthcare in England make Cytisine (cytisinicline) available as a treatment option alongside other established smoking cessation therapies, giving frontline healthcare professionals an additional treatment option in the fight against the ongoing smoking-related health crisis.(1)

"Cytisine is a real game-changer for smoking cessation," said Beverley Bostock, Advanced Nurse Practitioner, Mann Cottage Surgery, Gloucestershire. "Cytisine offers a short treatment duration compared to many other available treatments, and has a proven track record, making it a practical and effective option. With NICE's updated guidelines in place, clinicians will freely be able to provide this treatment option, where appropriate, to support more individuals in breaking free from smoking."

The update to the NICE tobacco guidelines was instigated by the UK launch of Cytisine in January 2024 and included a review of the clinical and cost-effectiveness evidence, which confirmed Cytisine's position as a first line treatment option for smoking cessation.(1)

"We can now add Cytisine to the list of treatments that, when combined with support from a trained professional, can help individuals to be smoke-free," said Professor Matthew Evison, Consultant Chest Physician at Wythenshawe Hospital. "Cytisine has a treatment duration of just 25 days and can be administered with a single prescription, meaning no need for repeat prescriptions or appointments for more tablets. Having more treatment options available, and making it easier for people who smoke to access them, will help ensure more people can be smoke-free, reducing the risk of illness and premature death."

Smoking remains a leading public health challenge in the UK, contributing to around 80,000 deaths annually and imposing a £21.8 billion economic burden.(2) Tobacco is the most preventable cause of ill health and death in the UK and, if further action is not taken, nearly half a million more people may die from smoking by 2030.(2),(3)

"Smoking is the leading cause of premature, preventable death in the UK," said Dr Gillian Lowrey, Respiratory Consultant at University Hospitals of Derby and Burton. "Cytisine gives healthcare professionals an additional stop smoking option to prescribe to patients, particularly those who want to avoid continued nicotine use. Many people prefer oral medications for convenience and Cytisine give them options."

Those wishing to quit smoking are encouraged to visit their local stop smoking services or speak with a healthcare professional to discuss treatment options.

UK-CYT-226
Date of Preparation: January 2025

Notes to Editors:

  • NICE Guidance NG209: https://www.nice.org.uk/guidance/ng209
  • Spokespersons are available for interview on request

About Cytisine

Cytisine (cytisinicline) is a prescription medication for smoking cessation, launched in the UK in January 2024. Its active ingredient, a plant alkaloid derived from the Cytisus laburnum plant, mimics nicotine, helping to reduce cravings and withdrawal symptoms while diminishing the pleasure of smoking.(4),(5)

Cytisine has been widely used in Eastern Europe for decades and is associated with a well-documented safety profile.(4),(6),(7) Since its introduction to the UK in January 2024, Cytisine has been recommended by AWMSG for use within NHS Wales for smoking cessation and reduction of nicotine cravings in smokers willing to stop smoking.(8) Cytisine has been recommended as a first choice stop smoking aid by the National Centre for Smoking Cessation and Training (NCSCT) in the latest version of 'Local Stop Smoking Services and support: commissioning, delivery and monitoring guidance', a comprehensive resource to support intelligence and evidence led decision making for smoking cessation.(9) The British Thoracic Society (BTS) included Cytisine as an effective nicotine analogue medication for tobacco dependency in its new framework for clinicians to help patients address their tobacco dependence during a hospital stay.(10)

Why the NICE Committee Made the Recommendation(1)

"The committee for the 2025 update to this guideline agreed to include cytisinicline, a medicinally licensed product, in the recommendations. Although the evidence base for cytisinicline ranged from moderate to very low quality, it was found to be effective in helping people to stop smoking when combined with behavioural support. It was found to be more effective than placebo or NRT, and there was no difference identified for the effectiveness of cytisinicline compared with varenicline.

When compared to placebo or no medication, and NRT, those taking cytisinicline were at higher risk of nausea and insomnia. But when varenicline was compared to cytisinicline, those taking varenicline were at greater risk of experiencing nausea. However, the absolute numbers for these differences were small and the committee. Noted that side effects like nausea and headache can also be symptoms of nicotine withdrawal. The available cost-effectiveness evidence, although limited, showed that cytisinicline, as with other stop smoking interventions, is likely to be cost-effective.

The committee also acknowledged that, because of the high costs and severe consequences of smoking-related diseases, most interventions that are clinically effective in smoking cessation, are cost-effective. When recommending cytisinicline the committee acknowledged the limited evidence in various population subgroups, particularly groups affected by health inequalities. The committee discussed adding a research recommendation on this area but agreed that the existing research recommendations in the guideline on stop smoking interventions for under-served groups and support for people with mental health conditions to stop smoking covered key gaps in the evidence."

About NICE Guidance NG209(1)

The first version of NICE guideline [NG209] "Tobacco: preventing uptake, promoting quitting and treating dependence" was published in 2021. The 2025 update reflects Cytisine's inclusion as a recommended treatment option following its UK launch and a comprehensive review of clinical evidence.

NICE's update mandates that local commissioners and providers of healthcare in England make Cytisine (cytisinicline) available as a treatment option alongside other established smoking cessation therapies, giving frontline healthcare professionals an additional treatment option in the fight against the ongoing smoking-related health crisis.(1)

Consilient Health  

Consilient Health is a medium-sized pharmaceutical company with a rich heritage of commercialising products in complex markets and in therapeutic areas such as women's health, endocrinology, bone health and urology among others. Since its establishment in 2005, its growth trajectory has been founded on forging robust partnerships with pharmaceutical manufacturers, ensuring market access, and adeptly marketing and distributing prescription healthcare products across Europe.

With the introduction of Cytisine into the smoking cessation market, Consilient Health hopes to facilitate a meaningful step towards reducing the burden of smoking on public health. Consilient Health is committed to supporting healthcare professionals with effective options and striving to improve outcomes for people seeking to quit smoking.

References:

1.  National Institute for Health and Care Excellence (NICE) Tobacco: preventing uptake, promoting quitting and treating dependence (NG209). February 2025 https://www.nice.org.uk/guidance/ng209 [Last Accessed: February 2025]

2.  UK Department of Health and Social Care. The Tobacco and Vapes Bill: What You Need to Know. Health Media Blog, 5 November 2024. Cited at: https://healthmedia.blog.gov.uk/2024/11/05/the-tobacco-and-vapes-bill-what-you-need-to-know [Last Accessed: February 2025]

3.  UK Government. The Khan Review. www.gov.uk/government/publications/the-khan-review-making-smoking-obsolete [Last Accessed: February 2025]

4.  Cytisine Summary of Product Characteristics (SmPC) Cited at: www.medicines.org.uk/emc/product/15789/smpc#gref [Last Accessed: February 2025]

5.  Livingstone-Banks J et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2023, Issue 5. Art. No.: CD006103.

6.  Prochaska JJ, Das S, Benowitz NL. Cytisine, the world's oldest smoking cessation aid. BMJ. 2013 Aug 23;347:f5198. doi: 10.1136/bmj.f5198. PMID: 23974638.

7.  Karnieg T et al. Cytisine for smoking cessation. CMAJ: 2018 Cited at: www.cmaj.ca/content/190/19/e596

8.  All Wales Medicines Strategy Group. All Wales Guide: Pharmacotherapy for smoking cessation, Feb 2018 (updated Nov 2024) Cited at: https://awttc.nhs.wales/files/guidelines-and-pils/all-wales-guide-pharmacotherapy-for-smoking-cessation-pdf/ [Last accessed: February 2025]

9.  NCSCT. Local Stop Smoking Services and support: commissioning, delivery and monitoring guidance. Cited at: https://www.ncsct.co.uk/publications/commissioning-delivery-monitoring [Last accessed: January 2025]

10.  Agrawal S, Evison M, Ananth S, et al. Medical management of inpatients with tobacco dependency. Thorax 2024;79 (suppl 1):3–11

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.